Elevance Health

Pricing power is present but constrained by regulation and competition. Elevance has historically passed trend in Commercial and secured rate actions in Government over time, but 2025 shows elevated medical trend in Medicare and ACA that is not immediately priced, pressuring margins.

Pharmacy cost inflation (notably GLP‑1 utilization) is an industry headwind, even as the firm deploys digital weight‑management programs and utilization controls. Net, Elevance exhibits steady, if regulated, price realization with limited latent pricing upside relative to monopolistic tollbooths.